HRP20190783T1 - Farmaceutske formulacije - Google Patents
Farmaceutske formulacije Download PDFInfo
- Publication number
- HRP20190783T1 HRP20190783T1 HRP20190783TT HRP20190783T HRP20190783T1 HR P20190783 T1 HRP20190783 T1 HR P20190783T1 HR P20190783T T HRP20190783T T HR P20190783TT HR P20190783 T HRP20190783 T HR P20190783T HR P20190783 T1 HRP20190783 T1 HR P20190783T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation
- percent
- weight
- amount
- formulation according
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 25
- 238000009472 formulation Methods 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000013078 crystal Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000035699 permeability Effects 0.000 claims 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- -1 carboxylate ion Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- 150000007529 inorganic bases Chemical class 0.000 claims 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 229960005480 sodium caprylate Drugs 0.000 claims 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 claims 1
- 229940082004 sodium laurate Drugs 0.000 claims 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (13)
1. Oralna farmaceutska formulacija koja sadrži spoj formule (I):
ili njegov kokristal; pri čemu je X- farmaceutski prihvatljiv anion odabran od halogenida ili karboksilatnog iona ili je X-odsutan;
a) sredstvo za povećanje propusnosti odabrano od natrijevog kaprilata, natrijevog kaprata, natrijevog laurata i natrijevog oleata ili
b) bazu odabrane iz organske baze, neorganske baze, fosfatnog pufera i soli karboksilne kiseline koja sadrži manje od 5 atoma ugljika ili
c) njihovu smjesu
i po izboru druge prihvatljive farmaceutske tvari.
2. Formulacija sukladno patentnom zahtjevu 1, pri čemu je halogenid klorid.
3. Formulacija sukladno patentnom zahtjevu 1, pri čemu je karboksilatni ion kaprat.
4. Formulacija sukladno patentnom zahtjevu 1, pri čemu je sredstvo za povećanje propusnosti natrijev kaprat.
5. Formulacija sukladno patentnom zahtjevu 1 ili 4, pri čemu je sredstvo za povećanje propusnosti prisutno u količini od 0,02 do 75 težinskih postotka ukupne formulacije; poželjno u količini od 2,5 do 60 težinskih postotaka ukupne formulacije; najpoželjnije u količini od 5 do 30 težinskih postotaka ukupne formulacije.
6. Formulacija sukladno patentnom zahtjevu 1, pri čemu je anorganska baza odabrana između magnezijum karbonata i natrijum bikarbonata.
7. Formulacija sukladno patentnom zahtjevu 1, pri čemu je organska baza izabrana između meglumina i arginina.
8. Formulacija sukladno patentnom zahtjevu 1, pri čemu je baza prisutna u količini od 0,002 do 60 težinskih postotaka ukupne formulacije, poželjno u količini od 0,2 do 25 težinskih postotaka ukupne formulacije, poželjnije u količini od 0,5 do 15,0 težinskih postotaka ukupne formulacije, najpoželjnije u količini od 0,5 do 5 težinskih postotaka ukupne formulacije.
9. Formulacija sukladno patentnom zahtjevu 1, pri čemu je spoj formule (I) i sredstvo za poboljšavanje propustljivosti u obliku konjugata.
10. Formulacija sukladno patentnom zahtjevu 1, pri čemu su jedinjenje formule (I) ili njegov kokristal prisutni u količini od 0,1 do 80 težinskih postotaka ukupne formulacije, poželjno u količini od 0,25 do 70 težinskih postotaka ukupne formulacije, najpoželjnije u količini od 5 do 50 težinskih postotaka ukupne formulacije.
11. Formulacija sukladno patentnom zahtjevu 1 za liječenju stanja odabranog između dijabetesa i makrovaskularnih i mikrovaskularnih komplikacija povezanih sa starenjem, uključujući zatajenje srca, nefrološki poremećaj, neuropatiju, aterosklerozu i retinalni poremećaj; dermatološki poremećaj; disfunkciju endotela ili drugih organa i poremećaj rasta.
12. Formulacija sukladno patentnom zahtjevu 1, pri čemu formulacija sadrži od 150 mg do 1500 spoja formule (I) ili njegovog kokristala.
13. Formulacija spoja formule (I) ili njegovog kokristala.12, pri čemu formulacija sadrži od 250 mg do 750 mg spoja formule (I) ili njegovog kokristala.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1475MU2015 | 2015-04-08 | ||
| EP16718474.6A EP3280447B1 (en) | 2015-04-08 | 2016-04-05 | Pharmaceutical formulations |
| PCT/IB2016/051920 WO2016162787A1 (en) | 2015-04-08 | 2016-04-05 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190783T1 true HRP20190783T1 (hr) | 2019-06-28 |
Family
ID=55808800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190783TT HRP20190783T1 (hr) | 2015-04-08 | 2019-04-26 | Farmaceutske formulacije |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10772879B2 (hr) |
| EP (1) | EP3280447B1 (hr) |
| JP (1) | JP6736656B2 (hr) |
| KR (1) | KR20170134662A (hr) |
| CN (1) | CN107530287B (hr) |
| AR (1) | AR104185A1 (hr) |
| AU (1) | AU2016246124B2 (hr) |
| BR (1) | BR112017021669A2 (hr) |
| CA (1) | CA2997463A1 (hr) |
| CY (1) | CY1121921T1 (hr) |
| DK (1) | DK3280447T3 (hr) |
| EA (1) | EA037041B1 (hr) |
| ES (1) | ES2724629T3 (hr) |
| HR (1) | HRP20190783T1 (hr) |
| HU (1) | HUE044889T2 (hr) |
| IL (1) | IL254794B (hr) |
| LT (1) | LT3280447T (hr) |
| MX (1) | MX2017012942A (hr) |
| MY (1) | MY182008A (hr) |
| PH (1) | PH12017501829A1 (hr) |
| PL (1) | PL3280447T3 (hr) |
| PT (1) | PT3280447T (hr) |
| RS (1) | RS58708B1 (hr) |
| SG (1) | SG11201708142XA (hr) |
| SI (1) | SI3280447T1 (hr) |
| TR (1) | TR201906476T4 (hr) |
| TW (1) | TWI713512B (hr) |
| UA (1) | UA123051C2 (hr) |
| WO (1) | WO2016162787A1 (hr) |
| ZA (1) | ZA201707094B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2876883C (en) | 2012-06-15 | 2022-11-01 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| EP2976072B9 (en) | 2013-03-22 | 2021-10-13 | Nova Southeastern University | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
| EP3866774A4 (en) * | 2018-10-19 | 2022-07-27 | Nova Southeastern University | SUBLINGUAL EPINEPHRINE COMPOSITIONS COMPRISING PH MODIFYING EXCIPIENTS AND PENETRATION ENHANCERS AND METHODS OF USE THEREOF |
| KR102330597B1 (ko) * | 2020-04-17 | 2021-11-26 | 보령제약 주식회사 | 무정형의 엠파글리플로진을 포함하는 안정성이 향상된 신규 약제학적 제형 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2363123C (en) * | 1999-02-22 | 2011-09-06 | Kenneth Iain Cumming | Solid oral dosage form containing an enhancer |
| AU769940B2 (en) * | 1999-10-06 | 2004-02-12 | Torrent Pharmaceuticals Ltd | Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| ES2243389T3 (es) | 2001-03-21 | 2005-12-01 | Torrent Pharmaceuticals Ltd | Compuestos de piridinio utiles para el tratamiento de enfermedades relacionadas con los age. |
| EP1996588A4 (en) | 2006-03-03 | 2011-10-05 | Torrent Pharmaceuticals Ltd | NEW DUAL ACTION RECEPTOR (DARA) ANTAGONISTS OF ATI AND ETA RECEPTORS |
| JP2009023932A (ja) * | 2007-07-18 | 2009-02-05 | Tama Tlo Kk | Ｎ−メチルピリジニウム化合物を有効成分として含有する抗ウイルス剤、それを含有する、抗ウイルス組成物、食餌及び動物用飼料 |
| JP2011510067A (ja) * | 2008-01-25 | 2011-03-31 | トレント・ファーマシューティカルズ・リミテッド | 組合せ医薬品 |
| CN101574343B (zh) * | 2008-05-07 | 2011-06-01 | 吉林大学 | 一种治疗糖尿病的药物组合物 |
| SG175422A1 (en) * | 2009-05-07 | 2011-11-28 | Torrent Pharmaceuticals Ltd | Piperidine derivatives useful for treatment of diebetes |
| CA2784120A1 (en) * | 2009-12-16 | 2011-07-14 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| CN104069066B (zh) * | 2013-03-25 | 2017-04-19 | 吉林大学 | 黄癸固体分散体及其在治疗糖尿病及并发症中的应用 |
-
2016
- 2016-04-05 LT LTEP16718474.6T patent/LT3280447T/lt unknown
- 2016-04-05 CA CA2997463A patent/CA2997463A1/en not_active Abandoned
- 2016-04-05 SG SG11201708142XA patent/SG11201708142XA/en unknown
- 2016-04-05 UA UAA201710864A patent/UA123051C2/uk unknown
- 2016-04-05 MY MYPI2017001475A patent/MY182008A/en unknown
- 2016-04-05 PL PL16718474T patent/PL3280447T3/pl unknown
- 2016-04-05 SI SI201630246T patent/SI3280447T1/sl unknown
- 2016-04-05 AR ARP160100918A patent/AR104185A1/es unknown
- 2016-04-05 HU HUE16718474 patent/HUE044889T2/hu unknown
- 2016-04-05 KR KR1020177032035A patent/KR20170134662A/ko not_active Application Discontinuation
- 2016-04-05 AU AU2016246124A patent/AU2016246124B2/en not_active Ceased
- 2016-04-05 MX MX2017012942A patent/MX2017012942A/es unknown
- 2016-04-05 EA EA201792237A patent/EA037041B1/ru unknown
- 2016-04-05 ES ES16718474T patent/ES2724629T3/es active Active
- 2016-04-05 TR TR2019/06476T patent/TR201906476T4/tr unknown
- 2016-04-05 BR BR112017021669A patent/BR112017021669A2/pt not_active Application Discontinuation
- 2016-04-05 EP EP16718474.6A patent/EP3280447B1/en active Active
- 2016-04-05 JP JP2018503835A patent/JP6736656B2/ja not_active Expired - Fee Related
- 2016-04-05 CN CN201680020704.2A patent/CN107530287B/zh not_active Expired - Fee Related
- 2016-04-05 DK DK16718474.6T patent/DK3280447T3/da active
- 2016-04-05 WO PCT/IB2016/051920 patent/WO2016162787A1/en active Application Filing
- 2016-04-05 US US15/564,720 patent/US10772879B2/en active Active
- 2016-04-05 PT PT16718474T patent/PT3280447T/pt unknown
- 2016-04-05 RS RS20190537A patent/RS58708B1/sr unknown
- 2016-04-06 TW TW105110715A patent/TWI713512B/zh active
-
2017
- 2017-09-28 IL IL254794A patent/IL254794B/en active IP Right Grant
- 2017-10-06 PH PH12017501829A patent/PH12017501829A1/en unknown
- 2017-10-19 ZA ZA2017/07094A patent/ZA201707094B/en unknown
-
2019
- 2019-04-26 HR HRP20190783TT patent/HRP20190783T1/hr unknown
- 2019-05-03 CY CY20191100471T patent/CY1121921T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190783T1 (hr) | Farmaceutske formulacije | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| JP2015506989A5 (hr) | ||
| EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
| MX2016006197A (es) | Formulaciones de compuestos de azaindol. | |
| JP2015527402A5 (hr) | ||
| BR112014029016A2 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| UA109421C2 (uk) | Фармацевтична композиція, яка містить ліганди сигма-рецептора | |
| BR112013014184A2 (pt) | compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso | |
| MX2015013051A (es) | 1-hidroxi-benzooxaboroles como agentes antiparasitarios. | |
| AR088195A1 (es) | Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| JP2015525762A5 (hr) | ||
| JP2016534153A5 (hr) | ||
| JP2013524782A5 (hr) | ||
| ZA201508924B (en) | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| EA201391325A1 (ru) | Новые производные цефалоспорина и их фармацевтические композиции | |
| BR112014001369A2 (pt) | derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral | |
| BR112015004523A2 (pt) | compostos de tetraciclina | |
| JP2017514924A5 (hr) |